Current research has centered around the role of nitric oxide in the stimulation of cavernosal vasodilation and erection. However, recent evidence from our lab details the importance of endogenous vasoconstrictor mechanisms in maintaining a¯accid penile state, and further demonstrates that the inhibition of endogenous vasoconstriction is suf®cient to stimulate erection in a rat model. In this article, we suggest inhibition of endogenous vasoconstriction as a potential therapeutic avenue in the treatment of erectile dysfunction. We also speculate on potential physiologic mechanisms by which endogenous vasoconstriction is inhibited in order for arousalinitiated vasorelaxation, and erection, to occur.
Introduction
The erectile state of the penis is determined by pressure changes in the cavernosal vasculature. The vasculature of the penis is unique as it is composed of a network of connective tissue surrounding sinuses lined with smooth muscle and endothelial cells. The smooth muscle and endothelial cells dynamically function to regulate the tone of the cavernous vasculature, and thus the¯ow of blood into the sinuses. Under basal conditions, cavernosal vasoconstriction minimizes blood¯ow and corpus cavernosum pressure (CCP) remains low, maintaining the penis in the¯accid state. 1,2 During erectile stimulation (predominantly through activation of non-adrenergicanon-cholinergic nerves) the release of nitric oxide (NO) initiates cavernosal smooth muscle relaxation, resulting ultimately in increased CCP and penile erection. 3 ± 6 Although this NOmediated pathway is thought to be the principal mechanism leading to erection, evidence also exists implicating the role of other vasodilators (acetylcholine 3, 4 and vasoactive intestinal peptide 7 ± 9 ), as well as various vasoconstrictors (norepinephrine 10 ± 13 and endothelin-1 14 ± 16 ), in the regulation of cavernosal tone. This paper will brie¯y outline the role of some of these known players, however, the bulk of this paper will be centered around describing a role for a novel calcium-sensitizing pathway, involving the small G-protein RhoA and a downstream target, Rho-kinase, in the maintenance of cavernosal vasoconstriction. Although much work has detailed the importance of the RhoAaRho-kinase contractile pathway in various forms of smooth muscle, the role of this pathway in cavernosal smooth muscle regulation has only recently been reported. 17 We hypothesize that the RhoAaRho-kinase pathway is critical to the maintenance of cavernosal vasoconstriction, and based on initial experimental results, speculate that the inhibition of this pathway is essential for the erectile response, and may serve as a potential (NO-independent) therapeutic avenue for the treatment of erectile dysfunction.
Mechanisms of cavernosal vasorelaxation
A variety of intracellular mechanisms can activate relaxation of the cavernous vasculature. Vasorelaxation is mainly characterized by a decline in myosin light chain (MLC) phosphorylation via suppressed MLC kinase activation (dependent or independent of a reduction in intracellular Ca ), andaor via enhanced MLC phosphatase activity. 18 It is widely accepted that NO, produced by the non-adrenergicanon-cholinergic innervation of the cavernosal vasculature and local endothelial cells, is the principal mediator of cavernosal smooth muscle relaxation. 3 ± 6 Regardless of the source, NO enters the smooth muscle cell and activates soluble guanylate cyclase, leading to an increase in cGMP levels. Subsequently, cGMP-dependent protein kinase (PKG) can alter intracellular Ca levels by reducing Ca channel activity and by opening Ca dependent K channels, leading to hyperpolarization of the smooth muscle cell. PKG can also phosphorylate other proteins to affect Ca channels or lead to the alteration of the phosphorylation state of MLC, altogether ultimately resulting in NO-mediated cavernosal smooth muscle relaxation. 19, 20 The relaxation of cavernosal arteriolar and sinus smooth muscle permits increased penile blood¯ow, which results in ®lling of the sinuses and the expansion of the erectile tissue. 21, 22 The increased blood¯ow is driven, therefore, by the force of the arterial blood pressure. The outer layer of the corpus cavernosum, the tunica albuginea, has the capacity (albeit limited) to expand in response to the force of blood pressure, so that the expansion results in an increased length and diameter of the penis. The initial rise in CCP also activates a pressuredependent veno-occlusive mechanism to limit the out¯ow of blood. Thus, with dilation of arterioles resulting in increased in¯ow coupled with the veno-occlusive-dependent decline in out¯ow, CCP rises, and the penis becomes erect. 21 In addition to NO, there is evidence that other vasodilator mechanisms may also contribute to the erectile response. Parasympathetic innervation of the penis releases acetylcholine (Ach), and this neurotransmitter may enhance erection by inhibiting the release of norepinephrine and by stimulating endothelial NO production. 3, 4, 23 Additionally, neurons containing vasoactive intestinal polypeptide (VIP) have been found in cavernosal tissue, and the administration of VIP leads to an increase in CCP, leading to erection. 7 ± 9 Components of the arachidonic acid metabolic pathway have also been localized in the penis, and it has long been suggested that prostaglandins may also contribute to the erectile response as PGE 1 has been used successfully in the treatment of erectile dysfunction. 24 
Mechanisms of cavernosal vasoconstriction
Smooth muscle in the cavernosal arterioles and sinuses contains a-adrenergic receptors and contracts in response to norepinephrine (NE) released from the sympathetic innervation of the penis. 10 ± 13 Activation of these a receptors on the cavernosal smooth muscle cells stimulates the dissociation of the G-protein receptor subunits, subsequently leading to activation of phospholipase C. This enzyme catalyzes the hydrolysis of phosphatidylinositol 4,5 bisphosphate (PIP 2 ) to form inositol triphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 then binds to the sarcoplasmic reticulum receptors, causing the release of Ca into the cytosol. In the presence of elevated intracellular Ca , DAG activates protein kinase C to further sustain the increase in intracellular Ca . Upon binding to calmodulin, Ca activates MLC kinase, resulting in the phosphorylation of MLC, and the interaction of myosin and actin. 18 It is generally believed that the penis is primarily kept in the non-erect (¯accid) state due to vasoconstrictor stimulation from the a-adrenergic nervous system. 10 ± 13 Another agent which potentially contributes to the continuous smooth muscle tone characteristic of the¯accid penis is endothelin-1 (ET-1), secreted by endothelial cells of the corpus cavernosum. ET-1 can bind to two receptor types, ET A and ET B , both of which have been identi®ed in cavernosal smooth muscle. 14 ± 16 ET-1 binding to ET A receptors leads to increased levels of intracellular Ca and vasocontraction, 15, 16, 25 while the binding of ET-1 to ET B receptors leads to the production of NO through eNOS activation, and thus vasorelaxation. 25 However, despite the demonstration of ET-1 speci®c receptors and reported vasoconstrictor effects of exogenous ET-1 on cavernosal tissues, the scope of ET-1's role in cavernosal vasoconstriction remains to be determined.
A component of both a-adrenergic and ET-1-mediated vasoconstriction is known to be dependent on the small G-protein, RhoA, and a downstream target, the SERaTHR kinase, Rhokinase. 26 The focus of the remainder of this paper will thus be the role of the RhoAaRho-kinase calcium-sensitizing vasoconstriction pathway in the regulation of cavernosal tone.
RhoAaRho-kinase and the calcium-sensitization of vascular smooth muscle
Numerous studies have established an important role for RhoA and Rho-kinase in numerous cellular responses, including the contraction of various cell types. 27 RhoAaRho-kinase activation of cellular responses including the regulation of the actin cytoskeleton, DNA transcription, and focal adhesiona stress ®ber formation, has been extensively reviewed elsewhere. 27 This paper, however, will focus on the potential effects of RhoAaRho-kinase-mediation of cellular contraction and penile¯accidity. In vitro studies have demonstrated the contractile effects of RhoAaRho-kinase to be the result of Rho-kinasemediated inhibition of myosin light chain phospha- this has yet to be demonstrated in vivo. 31, 33 Activation of this calcium-sensitizing pathway is regulated by the binding state of RhoA. Similar to other small GTPases from the Rho family, RhoA is activated upon the binding of guanosine triphosphate (GTP). In the inactive state, RhoA is primarily cytosolic, and is bound to guanosine diphosphate (GDP) and a guanine nucleotide dissociation inhibitor (GDI). 34 Post-translational modi®cation (geranylgeranylation) enables the necessary membrane binding and subsequent activation of RhoA. 28, 29, 34 Activation also requires a guanine nucleotide exchange factor (GEF) which promotes the exchange of GTP for GDP. 29 The in vitro and in vivo effects of RhoA and Rho-kinase have been elucidated mainly through pharmacological inhibitor studies. Various bacterial toxins, ie Clostridium botulinum C3 and Clostridium dif®cile toxin B, have been used to inhibit the effects of RhoA (via ADP ribosylation and UDP-glucosylation, respectively). 28, 29, 34 The activity of Rho-kinase has also been inhibited with the compound Y-27632, developed by Wel®de Corporation (Osaka, Japan). 26 This pyridine derivative has been shown to be 200 times more speci®c for Rho-kinase than other protein kinases such as protein kinase C, cAMPdependent protein kinase, PAK, and MLC kinase. 26, 35 Studies using these various antagonists have shown RhoAaRho-kinase to mediate vascular constrictor responses to agonists including phenylephrine, serotonin, ET-1, and histamine. 26 ,36 aAdrenergic agonists, and ET-1 have been shown to bind to receptors coupled to Ga q and Ga 12a13 . 37 Evidence exists demonstrating that Ga i , Ga q and Ga 12a13 G-proteins can activate some of their effects via RhoAaRho-kinase. 28,38 ± 40 More so, the subunits from Ga 12a13 have been shown to directly bind and activate RhoGEF (promoter of RhoA activity) providing mechanistic insight on the link between heterotrimeric and monomeric G-protein activity. 41 ± 43 Although the role of RhoAaRho-kinase has been well outlined in numerous forms of smooth muscle, only recently has evidence emerged demonstrating the importance of this pathway in the regulation of cavernosal smooth muscle tone. 17 
Initial results establishing the importance of Rho-kinase in cavernosal vasoconstriction
We have recently published evidence supporting the role of Rho-kinase in the maintenance of cavernosal smooth muscle vasoconstriction. 17 When administered directly into the sinuses of adult male rats, the Rho-kinase antagonist, Y-27632, increased CCPamean arterial pressure (MAP) in a dose-dependent manner. Treatment with Y-27632 also potentiated voltagestimulated (NO-mediated) increases in CCPaMAP, and this effect was not blocked by inhibitors of NOS or guanylate cyclase activity [N w -Nitro-L -Arginine (L-NNA) or N w -Nitro-L -Arginine Methyl Ester (L-NAME), and 1H-[1, 2, 4]oxadiazolo-[4, 3-a]quinoxalin-1-one (ODQ) or methylene blue, respectively], suggesting it is independent of a NO-mediated pathway. 17 We have also obtained additional in vivo data supporting that Rho-kinase activity mediates the response to exogenousET-1and thea-adrenergic agonist, methoxamine in the cavernosal circulation (unpublished). As discussed earlier, both a-adrenergic agonists and ET-1 are potent cavernosal smooth muscle vasoconstrictors, and thus when administered intracavernosally, inhibit voltage-stimulated increases in CCPaMAP. 15, 44 However, we have found both ET-1 and the aadrenergic agonists to be ineffective in inhibiting CCPaMAP in the presence of Y-27632 (unpublished). Through these results, and in agreement with ®ndings in the systemic vasculature, we speculate that endogenous vasoconstrictors such as NE and ET-1 require RhoAaRho-kinase activation to maintain cavernosal smooth muscle vasoconstriction.
In light of the strong vasoconstriction, how does erection ever occur?
As discussed, cavernosal smooth muscle vasoconstriction stimulated by sympathetic release of NE and plausibly the local release of ET-1, (both working partially through RhoAaRho-kinase activation), maintains the penis in the¯accid state. Upon sexual arousal, or during nocturnal penile tumescence events, stimulation of the non-adrenergicanon-cholinergic innervation of cavernosal tissue results in NO release, and vasorelaxation through cGMP-mediated activity. However, during this time, sympathetic nerve activity may not be decreased. Thus, the question remains as to how erection can ever occur in the presence of this strong sympathetic vasoconstriction. We hypothesize three potential mechanisms by which NO can stimulate cavernosal smooth muscle relaxation in the presence of continued sympathetic stimulation. These hypothetical mechanisms involve Ach, serotonin, and NO, however, the potential for additional or combinatorial mechanisms also exists.
As mentioned earlier, Ach releasing nerves innervate cavernosal tissue, and it has been established that Ach inhibits the release of NE from sympathetic nerve endings. 23 Ach also is a potent stimulator of eNOS, resulting in increased NO. Thus, it is plausible that Ach, released during the neural stimulation of erection, functions to RhoAaRho-kinase K Chitaley et al inhibit the vasoconstrictor effects of sympathetic stimulation in addition to increasing local NO. The inhibition of NE release could potentially block both the Ca -dependent contractile cascade, as well as the activation of the RhoAaRho-kinase calciumsensitizing pathway. Accordingly, levels of local NE release should be decreased during nervemediated erectile stimulation, facilitating the NOstimulated vasorelaxation, however this has yet to be veri®ed experimentally.
Another plausible hypothesis involves the local release of serotonin. Serotonin has been shown to be co-released with NE from sympathetic nerve endings, and also to potentiate the constrictor effects of NE. 45 Much evidence demonstrates that serotonin re-uptake inhibitors (SSRIs, often used to treat depression) can lead to erectile dysfunction. 46 Although this effect is primarily due to the inhibition of central nervous system-mediated arousal, the potential also exists for local effects of SSRIs on prolonging the presence of serotonin in the cavernosal tissue. When central nervous system-mediated erectile stimulation does occur, it is possible that released Ach inhibits serotonin release in addition to the co-transported NE from the sympathetic nerve endings.
The role of indirect actions of NO to inhibit basal CSM vasoconstriction (in addition to the cGMPmediated vasorelaxation) cannot be ruled out as a potential mechanism of inhibiting the basal cavernosal vasoconstriction seen in the¯accid state. Recent evidence demonstrates that protein kinase G (stimulated downstream of NO) can inhibit RhoA activity through direct phosphorylation in another smooth muscle system. 46 This inhibition would thus block a central calcium-sensitizing component of vasoconstriction. Despite these data, our recently published in vivo ®ndings suggest that the potentiating effects of Rho-kinase antagonism on the erectile response are unaltered by the presence of pharmacologic antagonists of the NO pathway.
Rho-kinase antagonism: a potential therapy for the treatment of erectile dysfunction Despite the success of sildena®l (Viagra, P®zer) in promoting cavernosal smooth muscle vasorelaxation, a recent report points to the need for additional research on potential treatments for erectile dysfunction. 48 Sildena®l works to selectively inhibit the type 5 phosphodiesterase, promoting increased cellular levels of cGMP. Despite the popularity of Viagra, a recent study shows that patients with severe erectile Figure 1 Proposed endogenous mechanisms of cavernosal smooth muscle vasoconstriction and penile¯accidity. NE released from sympathetic nerve endings, as well as the local release of ET-1, are integral in the maintenance of CSM vasoconstriction. NE and ET-1 binding to G-proteins coupled receptors of the Ga q andaor Ga 12a13 types may activate both calcium-dependent MLC phosphorylation as well the calcium-sensitizing RhoAaRho-kinase pathway.
RhoAaRho-kinase K Chitaley et al dysfunction, (as is often seen secondary to diabetes or prostate surgery) had only a modest 41% satisfaction rate with this treatment. 49 Additionally, in all patients studied, only 30% were satis®ed with oral Viagra therapy. 50 An alternative approach to treating erectile dysfunction may be found in the inhibition of the RhoAaRho-kinase calcium-sensitizing pathway. As discussed earlier, in vivo administration of the Rho-kinase antagonist, Y-27632, increased CCPaMAP even in the absence of erectile stimulation, and more so, at relevant doses, did not signi®cantly alter MAP 17 (consistent with the ®nd-ing of Uehata et al that per os treatment of Y-27632 decreases systemic blood pressure in hypertensive but not normotensive rats). 26 Although inhibition of RhoAaRho-kinase may lead to undesirable effects due to the diverse cellular functions of this pathway, local, transient inhibition may be of great potential bene®t in the treatment of erectile dysfunction.
Conclusion
The state of cavernosal smooth muscle tone regulates penile erection and¯accidity. NO is the well established primary stimulator of cavernosal smooth muscle relaxation and thus erection. In the absence of sexual arousal, however, strong vasoconstriction maintains the penis in the¯accid state. We hypothesize that this vasoconstriction is mediated in part by the RhoAaRho-kinase calcium-sensitizing pathway, and speculate on the mechanism(s) by which the intense basal cavernosal smooth muscle vasoconstriction is inhibited, allowing for and facilitating NO-mediated relaxation. Additionally, our results which show that endogenous Rho-kinase antagonism elicits and increases in CCPaMAP in vivo, demonstrates the importance of the RhoAaRho-kinase pathway in maintaining CSM vasoconstriction, pointing to a potential alternative therapy for the treatment of erectile dysfunction. RhoAaRho-kinase K Chitaley et al
